SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports that Nvidias board may remove Jensen Huang over alleged relationshipsincluding one involving a subordinate and another involving a suspected Chinese intelligence operativeare driving discussion, alongside congressional scrutiny. Traders are divided over whether leadership uncertainty and potential succession risks threaten the company or whether the selloff is an overreaction that leaves Nvidias AI business intact.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Reports that Nvidias board may oust Jensen Huang amid misconduct allegations have fueled a rotation into AMD, with traders viewing Nvidias leadership uncertainty as an opening for rivals. Others argue the headlines do not change chip competitiveness or AMDs fundamentals and see the sharp rally as excessive or vulnerable to a pullback.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Q3 earnings expectations dominate, with traders debating whether revenue growth will translate into improving margins, lower cash burn and credible guidance; bulls also point to elevated short interest as possible fuel for a squeeze, while skeptics cite dilution and execution risks. A new Digital Bat drone purchase order adds to the defense-growth case, though its value was not disclosed.

Quant (QNT) is a cryptocurrency and operates on the Ethereum platform. Quant has a current supply of 14,881,364 with 12,072,738 in circulation. The last known price of Quant is 167.55615276 USD and is down -7.61 over the last 24 hours. It is currently trading on 414 active market(s) with $110,681,799.54 traded over the last 24 hours. More information can be found at https://quant.network/.

Quant

QNTs sharp pullback and whether it can hold technical support dominate the discussion. Some traders are buying the dip and citing Quants limited supply and future banking-tokenization use case, while others expect further downside and link the pressure to weakness across crypto.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned FDA BLA for aglatimagene in localized prostate cancer is the dominant focus, backed by a positive Phase 3 result and recent immune-response and viral-clearance data discussed as support for the filing. Traders are divided between optimism about the regulatory and commercial opportunity and concerns over submission execution, management transparency, potential dilution, and weak share performance.

GraniteShares ETF Trust - GraniteShares 2x Long NVDA Daily ETF

GraniteShares 2x Long NVDA Daily ETF

NVDL is drawing attention as traders use its 2x daily exposure to Nvidia to trade the stocks sharp swings. Many are buying dips and anticipating a rebound, while others warn that volatility and leverage decay make it risky to hold.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is rallying with other neocloud stocks after CoreWeaves strong results and outlook eased concerns about AI demand and financing. Traders are focused on Nebiuss Q3 report, debating whether it can justify the run-up with growth and a credible funding plan or whether expectations are already priced in amid heavy capital-spending concerns.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves strong quarterly results and raised outlook sparked a sharp rally and lifted AI-infrastructure sentiment, but traders remain divided over whether heavy debt and funding needs undermine the growth story. Reports of turmoil involving Nvidia CEO Jensen Huang renewed concern about CoreWeaves Nvidia ties, while some traders argued the partnership and its contracts are larger than any one executive.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors rally is tied to managements confidence in deramiocel and an analyst upgrade ahead of the FDAs Nov. 22 decision on the therapy for Duchenne muscular dystrophy. Traders are speculating about approval and a possible short squeeze, while others stress that the outcome remains uncertain and could bring significant downside.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,961,030.37904498. The last known price of Zcash is 985.31210038 USD and is down -4.67 over the last 24 hours. It is currently trading on 670 active market(s) with $1,199,783,008.60 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcash is drawing attention after a sharp pullback following a major rally, with traders split between calling it a buying opportunity and warning that the decline could deepen. Some attribute the weakness to broader crypto-market risk-off and profit-taking, while bulls continue to cite Zcashs privacy features and recent network upgrade.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Raymond James reiterated $SRRK Strong Buy-$72 after Scholar Rock reported its 3Q26 financial results and provided a corporate update. 
[BIIB RHHBY NVS] 
Raymond James said in its note: Following its September 11, 2026, FDA approval, early demand for ISEMBYLD is off to a strong start, with the company reporting their first product revenues in the quarter. 
 
We continue to anticipate a robust U.S. commercial launch for ISEMBYLD, with revenues steadily ramping in 2027 as patient enrollments in the Scholar Rock Supports program swell and latency trends for time-to-infusion gradually shorten (with a product-specific J-code projected April 1, 2027, expected to significantly reduce this lag).

Truist reiterated $SRRK Buy-$77 and said -- SMA KOLs say 80% pts interested in Isembyld, expect 50-60% pts to be on drug in 5yrs; fractures not limiting 
$BIIB IONS RHHBY $NVS VYGR ARGX 
Truist added—We reiterate Buy on SRRK after KOL feedback supporting broad Isembyld uptake, with two KOLs guiding to ~60% and ~50% SMA patient penetration in five years. 
 
KOLs validated SAPPHIRE, highlighting ~33% responder rate at &gt;=3 points and real function (rolling, feeding, sitting). 
 
Both would prescribe broadly, favoring earlier patients, with ~80% patient interest cited. 
 
KOLs to watch fracture risk but don&#39;t view it as limiting; expect most neurologists to skip DEXA. 
 
On reimbursement, KOLs see potential for some pushback early on in launch, but expect drug to be covered, as seen with other SMA drugs. 
 
Both were skeptical on FSHD but flagged combo potential with disease modifiers.

StockTwits Web

Scholar Rock Holding Corp

Biogen Inc

Novartis AG

Quantumup

 Strong Buy-$72 after Scholar Rock reported its 3Q26 financial results and provided a corporate update. 
[BIIB RHHBY NVS] 
Raymond James said in its note: Following its September 11, 2026, FDA approval, early demand for ISEMBYLD is off to a strong start, with the company reporting their first product revenues in the quarter. 
 
We continue to anticipate a robust U.S. commercial launch for ISEMBYLD, with revenues steadily ramping in 2027 as patient enrollments in the Scholar Rock Supports program swell and latency trends for time-to-infusion gradually shorten (with a product-specific J-code projected April 1, 2027, expected to significantly reduce this lag).